Coldstream Capital Management’s NewAmsterdam Pharma NAMS Stock Holding History

Coldstream Capital Management’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24	Closed	-$492	–	2494
2025 Q1	$492	Buy	+24	New	+$533	﹤0.01%	3362

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Coldstream Capital Management's NAMS Position: Q2 2025 in Review

Coldstream Capital Management sold out of NewAmsterdam Pharma (NAMS) in Q2 2025, closing a stake of 24 shares — an estimated $492 sold.

Coldstream Capital Management first reported a position in NAMS in Q1 2025 and held it in 1 quarter. The position peaked at $492 in Q1 2025. 131 funds tracked by Wall St. Rank hold NAMS as of Q2 2025.

Coldstream Capital Management reported no remaining NewAmsterdam Pharma position as of Q2 2025 after selling out during the quarter.
Coldstream Capital Management sold 24 NewAmsterdam Pharma shares in Q2 2025, an estimated $492.
Coldstream Capital Management first reported a position in NewAmsterdam Pharma in Q1 2025 and held it in 1 quarter.
Coldstream Capital Management's NewAmsterdam Pharma position peaked at $492 in Q1 2025.
131 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.